← Back to headlines
CRISPR Therapeutics Shares Promising Early Data for Cholesterol Gene Therapy
CRISPR Therapeutics has presented initial clinical trial results for CTX310, a gene-editing treatment aimed at lowering triglycerides and LDL cholesterol, showing durable genetic modifications at the European Society of Cardiology congress.
28 Aug, 14:31 — 28 Aug, 14:36
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (24/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
investing-comtaiwan-news
Right
Far R
Geographic diversity— 2 regions9/34
US1Taiwan1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
investing-com22h ago
CRISPR Therapeutics reports one-year data for gene therapy CTX310
By Investing.com
Read full article →taiwan-newsMostly Factual23h ago
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - Taiwan News
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 Taiwan News
Read full article →Coverage Timeline
First report: taiwan-news · 28 Aug, 14:31|Full coverage: 2 · 6m|Window: 6m
Left-leaningCenterRight-leaning
